Sigilon focuses on type 1 diabetes, reduces spend on MPS-1 after letting CMO go

Sigilon Therapeutics said it decreased external spend on a rare lysosomal storage disorder as the Bob Langer-founded biotech focuses its cell therapy pipeline on type 1 diabetes.